BIOMOLECULAR LIFE HOLDINGS, INC.
Trading Symbol: BIOM CUSIP: 91822T200
1395 Brickell Avenue, Suite 800, Miami, Florida 33131

SUPPLEMENTAL INFORMATION AND DISCLOSURE STATEMENT

Related Party Transaction — Marketing Services and License Agreement

Dated August 7, 2026

---

1. Introduction

Biomolecular Life Holdings, Inc. (the "Company") is furnishing this supplemental disclosure to inform the market of a related party transaction the Company has entered into. This statement is provided in connection with the Company's disclosure obligations and is intended to be read together with the Company's other disclosures. The Company intends to describe this transaction, and to file the underlying agreement as an exhibit, in its registration statement on Form 10 and its subsequent periodic reports.

2. Description of the Transaction

Effective August 7, 2026, the Company entered into a Marketing Services and License Agreement (the "Agreement") with Biomolecular Life LLC ("BML"), a privately held Florida limited liability company that develops, markets, and sells a line of dietary supplement products for humans and pets under the "Biomolecular Life" brand. Under the Agreement, the Company manages the advertising, marketing, branding, and promotion of BML's supplement product line and receives a marketing fee equal to fifteen percent (15%) of BML's net revenue, payable quarterly. BML grants the Company a license to use the "Biomolecular Life" brand and related marks for all branding, marketing, and promotional purposes. The marketing fee is expected to be the Company's principal source of revenue.

3. Parties and Nature of the Related Party Relationship

The Agreement is a related party transaction. Jessika Contreras is the sole director and principal executive officer of the Company and holds voting control of the Company through Series A super-voting preferred stock held by The David and Jessika Contreras Living Trust. Ms. Contreras is also the sole manager of BML. Ms. Contreras executed the Agreement on behalf of both the Company and BML. Accordingly, the Company and BML are under common control, and no portion of the Agreement was negotiated between independent parties.

4. Material Terms

Effective date	August 7, 2026
Parties	Biomolecular Life Holdings, Inc. and Biomolecular Life LLC
Services	Advertising, marketing, branding, and promotion management for BML's supplement product line
Consideration to the Company	15% of BML net revenue, payable quarterly within 30 days after quarter end
License	Use of the "Biomolecular Life" brand for all branding, marketing, and promotional purposes
Term	One year, automatically renewing for successive one-year terms

Termination	30 days for convenience; for cause on uncured breach; automatically upon any business combination between the parties
Governing law	Florida

5. Interest of Management and Approval

Because Jessika Contreras serves as the sole director and officer of the Company and as the sole manager of BML, she has a direct interest in the Agreement on both sides. The Agreement was approved by written consent of the sole director of the Company and by written consent of the sole manager of BML. Each approval was made following full disclosure of Ms. Contreras's dual role, and each governing body determined that the terms of the Agreement are fair to the respective company and consistent with terms that could be obtained in a comparable transaction. The Company has no independent directors, and there was no independent review or approval of the Agreement.

6. Relationship to Any Future Transaction

The Company and BML share common branding and common control. The Company may in the future consider a business combination with, or acquisition of, BML. No agreement or binding commitment for any such transaction exists as of the date of this statement, and the Agreement described here neither commits the Company to nor prevents any such future transaction. The Agreement terminates automatically upon the closing of any business combination between the parties. Any such transaction, if pursued, would be subject to separate disclosure and to the applicable requirements at that time, including audited financial statements of the acquired business.

7. Risk Considerations

Investors should consider that the Company depends on a single related party for substantially all of its expected revenue; that the Agreement was not negotiated at arm's length and its terms may differ from those that would result from arm's-length negotiation; that the same individual controls both parties and there is no independent oversight of the relationship; and that the Agreement may be terminated by either party on 30 days notice, which would remove the Company's principal source of revenue.

8. Additional Information

The Marketing Services and License Agreement, and the written consents approving it, are available from the Company and are expected to be filed as exhibits to the Company's registration statement on Form 10. Questions regarding this statement may be directed to the Company at info@biomolecularlife.com.

9. Certification

I, Jessika Contreras, certify that:

(1) I have reviewed this Supplemental Information and Disclosure Statement of Biomolecular Life Holdings, Inc.;

(2) Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading with respect to the period covered by this disclosure statement; and

(3) Based on my knowledge, the financial information included or incorporated by reference in this disclosure statement fairly presents in all material respects the financial condition, results of operations, and cash flows of the Company as of, and for, the periods presented.

BIOMOLECULAR LIFE HOLDINGS, INC.

By: /s/ Jessika Contreras
Name: Jessika Contreras
Title: President and Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)
Date: August 7, 2026